Meeting Banner
Abstract #3710

Ultra-high field MRI enables the in vivo quantification of the efficacy of candidate promyelinating molecules in the cuprizone mouse model

Isaac Mawusi Adanyeguh1, Emilie Poirion1, Daniel GarcĂ­a-Lorenzo2, Marie-Stephane Aigrot1, Brahim Nait-Oumesmar1, Boris Zalc1, Alexandra Petiet1,2, and Bruno Stankoff1,3

1Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Brain and Spine Institute, ICM, F-75013, Paris, France, Paris, France, 2Center for NeuroImaging Research (CENIR), Brain and Spine Institute, 75013 Paris, France, Paris, France, 3AP-HP, Saint Antoine Hospital, Department of Neurology, 184 bd Faubourg Saint Antoine, 75012 Paris, Paris, France

Endogenous remyelination can potentially restore rapid axonal-conduction and confer neuroprotection in chronic demyelinating diseases such as multiple sclerosis. We used T2 mapping to evaluate the ability of two candidate pharmacological agents to promote remyelination in cuprizone-demyelinated mice. Demyelination was associated with increase in signal intensity and T2 values in the corpus callosum and external capsules. T2 values showed spontaneous recovery after discontinuation of cuprizone treatment, an effect accelerated following administration of the two compounds tested. This study confirms that in vivo MRI can be used to select pharmacological agents for their therapeutic potential on remyelination.

This abstract and the presentation materials are available to members only; a login is required.

Join Here